Aziz Mottiwala
CIK: 0001788542
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jul 24, 2026RXST
RxSight, Inc.
Award(A)DirectRestricted Stock Unit
2.3M shares- - Jul 24, 2026RXST
RxSight, Inc.
Award(A)DirectStock Option (right to buy)
571.3K shares- - Mar 19, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct4.4K shares at avg. $67.00$297K - Mar 18, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct4.3K shares at avg. $68.71$298K - Mar 17, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct4.3K shares at avg. $69.42$298K - Mar 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct26.5K shares- - Mar 5, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30.7K shares- - Mar 5, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
19.3K shares- - Jun 9, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct17.5K shares at avg. $43.76$766K - Mar 20, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct3.4K shares at avg. $50.11$169K - Mar 19, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct3.6K shares at avg. $47.40$169K - Mar 18, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct3.6K shares at avg. $46.29$169K - Mar 15, 2025TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct21K shares- - Mar 5, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
22.1K shares- - Mar 5, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
33.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 24, 2026 |  RXST RxSight, Inc. | Award(A) Restricted Stock Unit | 2,312,138 | - | - | Direct |
| Jul 24, 2026 | RXST RxSight, Inc. | Award(A) Stock Option (right to buy) | 571,286 | - | - | Direct |
| Mar 19, 2026 |  TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 4,440 | $67.00 | $297,480 | Direct |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 4,330 | $68.71 | $297,514 | Direct |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 4,286 | $69.42 | $297,534 | Direct |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 26,482 | - | $0 | Direct |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,724 | - | - | Direct |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 19,306 | - | - | Direct |
| Jun 9, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 17,500 | $43.76 | $765,800 | Direct |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 3,365 | $50.11 | $168,620 | Direct |
| Mar 19, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 3,557 | $47.40 | $168,602 | Direct |
| Mar 18, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 3,643 | $46.29 | $168,634 | Direct |
| Mar 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 20,957 | - | - | Direct |
| Mar 5, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 22,098 | - | - | Direct |
| Mar 5, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 33,691 | - | - | Direct |
1-15 of 15 transactions
About Mottiwala Aziz
Mottiwala Aziz (SEC CIK 0001788542) files insider reports with the SEC as President and CEO of RxSight, Inc. (RXST) and Chief Commercial Officer of Tarsus Pharmaceuticals, Inc. (TARS).
Signal8 holds 9 ownership filings by Mottiwala Aziz (1 Form 3, 8 Form 4), filed between Mar 7, 2025 and Jul 24, 2026. Those filings report 15 transactions, from Mar 5, 2025 to Jul 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Mottiwala Aziz's filings is in ALISO VIEJO, CA.
Recent filings by Mottiwala Aziz
- Jul 24, 2026: Grants or awards of RXST derivative securities (2 lines, Form 4, code A).
- Mar 19, 2026: Open-market sale of TARS shares (Form 4, code S).
- Mar 18, 2026: Open-market sale of TARS shares (Form 4, code S).
- Mar 17, 2026: Open-market sale of TARS shares (Form 4, code S).
- Mar 15, 2026: Option exercise of TARS shares (Form 4, code M).
Other insiders filing for RxSight, Inc. (RXST)
- Weinberg Eric
- Wilterding Mark, Chief Financial Officer
- Kurtz Ronald M MD, Chief Medical Officer
- Goldshleger Ilya, Chief Operating Officer
- Warner Robert Keith, Director
- PALMISANO ROBERT J, Director